HIV

The increased risk of cancer is due in part to people living with HIV living longer, thanks to advances like antiretroviral therapy.

Study examines the role of liver macrophages as a long-lived HIV-1 cellular reservoir.

Combination antiretroviral therapy (ART) has greatly reduced HIV-associated morbidity and mortality and improved the quality of life for those living with HIV.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

A pair of new studies is shedding light on a rare, but scientifically important, group of people with HIV who are able to maintain viral control even after stopping antiretroviral therapy.

Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.

A national survey demonstrated gaps in medical providers’ knowledge about changes to HIV health care delivery due to the Affordable Care Act.

More than 65% of patients with Kaposi’s sarcoma in a small cohort had partial or complete remission when treated with immune checkpoint inhibitors.

A new study examining HIV in people who inject drugs found interventions increased use of antiretroviral medication.

The years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

Through their Medicaid and Ryan White HIV/AIDS Programs, states play an integral role in ensuring access to care for people living with HIV.

Officials with the FDA approved Merck’s doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) tablet and doravirine (Pifeltro) for the treatment of HIV-1.

The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.

The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.

Pharmacists can help eliminate certain barriers to condom use by understanding the range of products available.

Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.

The study's findings show that patients with HIV will forgo short travel distances and wait times in order to access a health care provider with a positive attitude.

A new HIV therapy demonstrated its efficacy in reducing the virus and boosting immunity in drug-resistant patients, according to a recent published study.

Phase 3 study results showed that the new HIV therapy ibalizumab reduced viral replication and increased immunity in drug-resistant patients.

According to a recent study, older adults and Hispanics are less likely to receive HIV testing, indicating an urgent need for improved interventions.

Interventions must address HIV testing and beliefs among both patients and providers in order to reach underserved populations.

Patients with HIV have a high likelihood of developing depression related to their diagnosis, according to a recent study., and many of them do not seek medical care.

New research demonstrates continued virologic control in patients with HIV-1 following a switch to Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg [D/C/F/TAF]) regardless of prior treatment regimen

Clinical data demonstrate continued virologic response rates in patients with HIV switching to Symtuza from boosted protease inhibitor-based regimens.